Mammary Cell News Volume 4.11 | Mar 22 2012

LABORATORY RESEARCH

Targeting Chk1 in p53-Deficient Triple-Negative Breast Cancer Is Therapeutically Beneficial in Human-in-Mouse Tumor Models
Researchers tested whether inhibition of checkpoint kinase 1 (Chk1) could potentiate the cytotoxicity of the DNA damaging agent irinotecan in triple-negative breast cancer using xenotransplant tumor models. [J Clin Invest] Abstract | Press Release

Steroid Receptor Coactivator 3 Regulates Autophagy in Breast Cancer Cells through Macrophage Migration Inhibitory Factor
Researchers identified macrophage migration inhibitory factor (MIF) as a novel target gene of steroid receptor coactivator 3 and demonstrated its importance in cell survival. Specifically, they showed that MIF is a strong suppressor of autophagic cell death. [Cell Res] Abstract

Peroxiredoxin 2 Specifically Regulates the Oxidative and Metabolic Stress Response of Human Metastatic Breast Cancer Cells in Lungs
Researchers hypothesized that cancer cells that live under aerobic conditions, as might be the case in lungs, protect themselves against the damage caused by reactive oxygen species. [Oncogene] Abstract

Loss of Giant Obscurins Promotes Breast Epithelial Cell Survival through Apoptotic Resistance
Scientists studied the expression profile of obscurins in breast, colon, and skin cancer cell lines and their involvement in cell survival. [FASEB J] Abstract | Press Release

Insulin-Like Growth Factor 1 Attenuates Antiestrogen- and Antiprogestin-Induced Apoptosis in Estrogen Receptor Positive Breast Cancer Cells by MEK1 Regulation of the BH3-Only Pro-Apoptotic Protein Bim
Researchers’ goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulin-like growth factor-1. [Breast Cancer Res] Abstract

Inhibition of Phosphatidylcholine-Specific Phospholipase C Results in Loss of Mesenchymal Traits in Metastatic Breast Cancer Cells
Researchers investigated the effects of D609, a xanthate inhibiting phosphatidylcholine-specific phospholipase C and sphingomyelin synthase, as a candidate regulator of cell differentiation and mesenchymal-epithelial transition in the highly metastatic breast cancer cell line MDA-MB-231. [Breast Cancer Res] Abstract

Both Lrp5 and Lrp6 Receptors Are Required to Respond to Physiological Wnt Ligands in Mammary Epithelial Cells (and Fibroblasts)
Researchers show that at endogenous levels of lipoprotein like receptor 5 (Lrp5) and Lrp6, both receptors are required to signal in response to some Wnt ligands, both in vitro (in mouse embryonic fibroblasts and mammary epithelial cells) and in vivo (in mammary outgrowths). [J Biol Chem] Abstract

Anandamide Inhibits the Wnt/β-Catenin Signaling Pathway in Human Breast Cancer MDA MB 231 Cells
As accumulating evidences indicate that the constitutive activation of the canonical Wnt pathway in human breast cancer may highlight a key role for aberrant activation of the β-catenin-T cell factor cascade and tumor progression, researchers studied the anandamide effect on the key elements of Wnt pathway in breast cancer cells. [Eur J Cancer] Abstract

CLINICAL RESEARCH

FOXP3 Expression in Cancer Cells and Anthracyclines Efficacy in Patients with Primary Breast Cancer Treated with Adjuvant Chemotherapy in the Phase III UNICANCER-PACS 01 Trial
Scientists hypothesized that forkhead box protein 3 (FOXP3) expression predicts the response to anthracyclines in breast cancer patients and that adjuvant chemotherapy adding taxanes to anthracyclines confers an overall survival benefit over anthracyclines alone, in patients with FOXP3-negative tumors. [Ann Oncol] Abstract

A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer
This trial estimates the antitumor efficacy and toxicity of the EGFR tyrosine kinase inhibitor gefitinib in combination with anastrozole or fulvestrant in postmenopausal hormone receptor positive breast cancer. [Breast Cancer Res Treat] Abstract

Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72^nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72^nd Scientific Sessions, Philadelphia] Press Release

iCAD Launches Post-Market Study of Intra-Operative Radiation Therapy to Treat Early Stage Breast Cancer
iCAD, Inc. announced the launch of a post-market study to assess the safety and efficacy of the company’s FDA-cleared Xoft Axxent® eBx™ System when used for single-fraction, intra-operative radiation therapy at the time of lumpectomy for early stage breast cancer. [iCAD, Inc.] Press Release

The Breast Cancer Research Foundation Announces New Board Appointments
The Breast Cancer Research Foundation announced the election of three new members to its Board of Directors. [PR Newswire] Press Release

Galena Biopharma Announces Addition of Renowned Breast Cancer Physician to Its Scientific Advisory Board
Galena Biopharma announced the appointment of Hope S. Rugo, M.D. to the Company’s Scientific Advisory Board. [Galena Biopharma] Press Release

NEW 2012 Breast Cancer Symposium
September 13-15, 2012
San Francisco, United States

NEW San Antonio Breast Cancer Symposium
December 4-8, 2012
San Antonio, United States

Visit our events page to see a complete list of events in the mammary cell community.

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Tenure Track Position (Johns Hopkins University)

Research Associate (Imperial College London)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)

Postdoctoral Position – Breast Cancer Cell Biology (Karolinska Institutet) 

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati – College of Medicine)

Postdoctoral Research Fellow (Cancer Research UK – Cambridge Research Institute) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.